Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20117 combination therapy in advanced solid tumors
NCT06621563Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Dec 2024
- Primary completion
- Mar 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HS-20117-2 in solid tumor, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (6 cohorts), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Treatment-Emergent Adverse Events, Dose Limiting Toxicity and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
HS-20117-2
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06621563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06621563.